Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIa, Multicenter, Open-label Study to Assess the Safety and Efficacy of the Combination of BL-8040 and Pembrolizumab in Patients With Metastatic Pancreatic Cancer, the COMBAT Study (KEYNOTE-202)

NCT02826486 is registered in ClinicalTrials.gov with BioLineRx, Ltd. as lead sponsor.

NCT NCT02826486
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02826486 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIa, Multicenter, Open-label Study to Assess the Safety and Efficacy of the Combination of BL-8040 and Pembrolizumab in Patients With Metastatic Pancreatic Cancer, the COMBAT Study (KEYNOTE-202)
Lead sponsor
BioLineRx, Ltd.
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2016
Completion date
September 6, 2022
Enrollment
80 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic pancreatic adenocarcinoma